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Abstract
At the end of June 2018, small amounts of a highly carcinogenic N–nitrosamine, N–nitrosodimethylamine (NDMA), were 
found to contaminate some angiotensin receptor blockers (sartans) used for the treatment of arterial hypertension. 
By July 2019, four N-nitrosamine impurities were identified in sartans, including NDMA, N–nitrosodiethylamine, N–ni-
trosodiisopropylamine and N-nitroso-N-methyl-4-aminobutyric acid. Seven manufacturers of three contaminated active 
substances (valsartan, losartan and irbesartan) from China, India and Mexico were also identified. These compounds 
had infiltrated the active pharmaceutical ingredients probably as a consequence of ill-considered synthesis modifica-
tions. The number of people who have been prescribed contaminated valsartan alone has been estimated at around 
20 million worldwide. 
This paper discusses the therapeutic role of sartans in the context of the physiological significance of the renin–angiotensin– 
–aldosterone system as well as the role of tetrazole moiety in the mechanism of sartan receptor activity. The synthesis 
of tetrazole moiety and its modifications have been characterized as possible causes of the appearance of nitrosamine 
impurities in sartans. The toxicological properties of nitrosamines are also briefly outlined. The fact that nitrosamines had 
been entering medicines for at least five years undetected and outside the knowledge of the authorities responsible for drug 
safety has exposed a gross malfunctioning of the system intended to guarantee the safety of medicinal products. As a result, 
the valsartan scandal has forced changes to some drug regulations, in particular the requirements for analytical procedures.
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Introduction
In July 2018, the public opinion worldwide has been 
alarmed by detection of small amounts of potentially 
highly carcinogenic N–nitrosamines in some angiotensin 
II receptor AT1 blockers (sartans) used for the treatment 
of arterial hypertension. These contaminations had been 
entering medicines for at least five years undetected and 
outside the knowledge of the authorities responsible for 
drug safety, and the number of people who have been 
prescribed contaminated valsartan alone was estimated 
in January 2019 at around 20 million worldwide [1]. The 
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Physiological role of the  
renin–angiotensin–aldosterone system  
and the effect of sartans on this system
The renin–angiotensin–aldosterone system (RAAS), a hor-
monal and enzymatic system activated by a renal hormone 
renin, is one of the most important body systems regulating 
vascular smooth muscle tone and water and electrolyte 
balance (and thus also blood pressure). Increased RAAS 
activity leads to increased vascular smooth muscle tone, 
reduced urinary sodium and water excretion, and increased 
urinary potassium excretion, all leading to an increase in 
blood pressure [9, 10].
The key pressor RAAS component is an octapeptide an-
giotensin II (Ang II) which increases blood pressure mostly 
by activating specific angiotensin II type 1 receptor (AT1R). 
Understanding of the role of Ang II in the regulation of the 
cardiovascular system (CVS) led to a search for synthetic 
compounds with a high affinity for AT1R, characterized by 
a significant structural resemblance to Ang II but lacking 
its agonist effect. As the initial attempts to develop peptide 
structure-based drugs failed, researchers focused on com-
pounds containing several connected rings, the structure 
of which in body fluids bore sufficient resemblance to the 
stereochemical structure of aminoacids forming Ang II. This 
has led to the development of losartan (on the market sin-
ce 1994), followed by other non-peptide AT1R antagonists, 
also known as sartans, that entered the clinical practice. 
Currently, more than ten sartans are available, including 
azilsartan, eprosartan, irbesartan, candesartan, losartan, 
olmesartan, telmisartan and valsartan that have been 
marketed in Poland/EU. They are indicated for several cli-
nical conditions — all are used to lower blood pressure in 
arterial hypertension (AH), and some have been licensed 
to treat heart failure (HF) or left ventricular systolic dysfun-
ction, concomitant renal disease in patients with AH and 
diabetes type 2, and prevention of stroke in adult patients 
with AH. Valsartan, which is the major sartan discussed 
in the present paper, is used in Poland for the treatment 
of essential AH, some cases of symptomatic HF in adults, 
and asymptomatic left ventricular systolic dysfunction after 
recent myocardial infarction. Currently, a significant trend 
can be observed to extend indications for sartans beyond 
CVS treatment [11].
Structural components of sartans  
and their receptor binding
To provide desired angiotensin receptor antagonist effects 
at the molecular level, i.e., binding to AT1R and blocking this 
receptor, the structure of most sartans used in the clinical 
practice includes several main functional moieties, of which 
most important are three: a biphenyl-methyl moiety forming 
underlying cause was an ill-considered modification of the 
synthesis of tetrazole ring, present in the structure of most 
sartans, which is formed during one of the last steps of 
sartan synthesis. As a result, many sartan lots were recalled 
from the market in multiple countries, and companies 
producing both pharmaceutical products and their active 
ingredients were subjected to inspections. These events 
have had ongoing consequences, and investigations have 
been undertaken to evaluate the true size of this problem 
and the number of exposed people, and to determine the 
underlying causes [2–5].
The present paper discusses likely chemical mecha-
nisms of N–nitrosamine contamination, its toxicological 
and analytical aspects, and also provides the necessary 
background pharmacological and physiological information.
Detected N–nitrosamines, contaminated 
active pharmaceutical ingredients  
and their manufacturers
In June 2018, the Food and Drug Administration (FDA) 
received information that an U.S. company, Prinston 
Pharmaceuticals Inc., dba Solco Healthcare LLC., stopped 
manufacturing its valsartan products, as trace amounts 
of N–nitrosodimethylamine (NDMA) were detected in an 
active ingredient purchased from one of its manufacturers 
in China, Zhejiang Huahai Pharmaceutical Co., Ltd. (ZHP). 
On July 17, 2018, the company voluntarily recalled all its 
valsartan products from the market [6, 7]. During the same 
month, also the European Union (EU) authorities were 
informed that ZHP detected the presence of previously un-
noted technological contamination with NDMA in an active 
pharmaceutical ingredient (API), valsartan manufactured 
in a factory in Chuannan, China [8]. Detection of NMDA 
in valsartan initiated the so-called valsartan scandal and 
resulted in inspections performed in many countries that 
included not only a growing number of valsartan product 
lots (with their subsequent recall in large amounts, inclu-
ding of fixed-dose combinations, in several dozen countries 
[3]) but also other sartan products and API suppliers, as the 
regulatory authorities believed it was necessary to inspect 
closely all substances utilised during the drug synthesis. 
As a result, other nitrosamines in addition to NDMA, inclu-
ding N–nitrosodiethylamine (NDEA), N–nitrosodiisopropy-
lamine (NDIPA) and N–nitroso-N-methyl-4-aminobutyric 
acid (NMBA) were soon detected in several other sartans. 
The extent of the recall increased, and the number of 
manufacturers of contaminated API grew to seven in three 
different countries. Details on location and sources of API 
contamination are shown in Table 1.
The therapeutic importance of sartans calls for a sum-
mary of the physiological and pharmacological background 
of their action.
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the basic axis of sartan structure (of eight sartans listed 
above, only eprosartan is lacking this moiety), imidazole 
ring (absent only in valsartan), and aromatic 1H-tetrazole 
or 2H-tetrazole moiety at the 5-position [12]. The three 
above moieties bind to various domains of AT1R [13]. The 
tetrazole moiety seems of key importance as its presence 
is particularly important for the sartan antagonist effect on 
AT1R [13]. The tetrazole moiety is present in five (irbesar-
tan, candesartan, losartan, olmesartan, valsartan) of eight 
sartans that have been widely marketed [12].
Structure of tetrazole moiety  
and its location in the sartan structure
The above mentioned functional moieties responsible for 
the action of sartans at the molecular level are shown in 
Figure 1, depicting the structure of valsartan, and in Figu-
re 2, depicting the structure of the first developed drug of 
this class, losartan. In the valsartan molecule, N-acyl valine 
has been substituted for the imidazole ring.
Synthesis of the tetrazole moiety
Sartans can be synthesized by various pathways [14–16], 
and the selected method affects the possibility of forma-
tion of dangerous by-products. To understand the process 
of sartan N–nitrosamine contamination, it is necessary to 
review synthesis of the tetrazole ring, as N–nitrosamines 
may be generated during that step. Tetrazole ring synthesis 
in sartan molecules is based on a general principle whereby 
nitrils (organic hydrogen cyanide [HCN] derivatives, R-CN) 
may react, using various methods, with some organic or 
Table 1. List of contaminated sartans including manufacturers of drugs with contaminated active pharmaceutical ingredient (API)  
and the timing of impurity reporting
Sartan Impurity Manufacturer of contaminated 
API (name and country)
Reporting agency Date* of impurity reporting  
and reference***
Valsartan NDMA
ZHP, China US FDA June 2018 [6, 7]
EMA following ZHP June 2018 [8]
ZTP, China EMA, EDQM** 10.08.2018 [a]–28.08.2018 [b]
ZChP, China EDQM** 28.08.2018 [b]
Hetero Labs, India EDQM**
US FDA
28.08.2018 [b]
20.12.2018 [c]
Valsartan NDEA
ZHP, China EMA, US FDA 13.09.2018 [d, e]
Mylan, India EMA, EDQM**
US FDA
19.11.2018 [f, g]
21.11.2018 [h]
Aurobindo, India EDQM**
US FDA
Before 24.12.2018 [i]
2.01.2019 [j]
Valsartan NDIPA Signa S.A., Mexico TGA, EDQM** 18.12.2018 TGA [i, k]
Irbesartan NDEA
Aurobindo, India EDQM**
EMA, US FDA
Before 8.10.2018 [l]
15.10.2018 [m]–30.10.2018 [n]
ZHP, China EDQM**, FDA 18.01.2019 [o, p]
Losartan  
potassium
NDEA
ZHP, China US FDA
EDQM**
9.11.2018 [r]
18.01.2019 [o]
Hetero Labs, India EDQM**,
EMA,
US FDA
Before 17.10.2018 [l]
Before 21.09.2018 [s]
25.02.2019 [t]
Losartan  
potassium
NMBA Hetero Labs, India EDQM**, FDA 4.02.2019 [u]–28.02.2019 [w]
*First reporting of a given impurity by a drug agency in general or the first reporting of an impurity in API from a given manufacturer. Due to differences in dates reported in references, dates shown in the 
table should be considered approximate; **in cases monitored by the European Directorate for the Quality of Medicines & HealthCare (EDQM), this agency immediately suspended manufacturers’ certifi-
cates of suitability (CEP) that confirm compliance with the European Pharmacopoeia requirements; by this mechanism, 11 CEP were suspended by mid-May 2019; ***due to their large volume, references 
to materials published by the United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), EDQM and other agencies that appear only in Table 1 and not in the main text are 
available in a supplementary file available on-line. These references are marked with alphabet letters in square brackets, in the order of their appearance in the table; Aurobindo — Aurobindo Pharma Limited 
(India); Hetero Labs — Hetero Labs Limited (India); Mylan — Mylan Laboratories Ltd. (India); NDEA — N–nitrosodiethylamine; NDIPA — N–nitrosodiisopropylamine; NDMA — N–nitrosodimethylamine; NMBA 
— N–nitroso-N-methyl-4-aminobutyric acid; Signa S.A. — Signa S.A. de C.V. (Toluca, Mexico, member of Apotex Pharmachem Group); TGA — The Therapeutic Goods Administration (Australia); ZChP — Zhejiang 
Changming Pharmaceutical Co., Ltd. (China); ZHP — Zhejiang Huahai Pharmaceutical Co., Ltd. (China); ZTP — Zhejiang Tianyu Pharmaceutical Co., Ltd. (China)
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Figure 1. Structural formula of valsartan or N-(1-oxopentyl)-N-[[2’-
(2H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-L-valine (International 
Union of Pure and Applied Chemistry [IUPAC] name: (S)-3-methyl-2- 
-(N-{[2’-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)
butanoic acid). Functional moieties providing the angiotensin II 
receptor antagonist effect at the molecular level were marked in 
colours: the biphenyl-methyl moiety with yellow; the 2H-tetrazole 
moiety at the 5-position with purple. Only selected atoms relevant 
for the text discussion are numbered
Figure 2. Structural formula of losartan or (2-butyl-4-chloro-1-{[2’-
-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol 
(IUPAC name). Functional moieties providing the angiotensin II 
receptor antagonist effect at the molecular level were marked in 
colours: the biphenyl-methyl moiety with yellow; the imidazole ring 
with blue; the 2H-tetrazole moiety at the 5-position with purple. 
Only selected atoms relevant for the text discussion are numbered
Following the above reaction, the only next step needed 
is hydrolysis of the resultant stannyl tetrazole compound 
(Figure 3C), yielding the actual API — valsartan.
Possible causes of sartan contamination 
with N–nitrosamines
In addition to the above method of sartan synthesis, other 
methods to synthesize the tetrazole ring exist, including 
those based on the reactions of nitrils with organic or 
inorganic azides described above [19, 20]. These mul-
tiple pathways leading to the same end-product create 
an opportunity to introduce many technologically simple 
modifications of the sartan synthesis process, including 
that of valsartan, even within the same patent-protected 
solution (see, e.g., patents number CN104045602A [20] 
and WO2012001484A2 [21]). In fact, some changes in 
reagents or solvents are often allowed in patent specifica-
tions. However, if all potential side reactions are not fore-
seen, such modifications may lead to errors in synthesis, 
which was likely the cause of sartan contamination with 
N–nitrosamines.
A wide search of patent specifications performed by 
German authors Buschmann and Holzgrabe [18] after 
detection of nitrosamines in valsartan has indicated with 
a high likelihood that the Chinese manufacturer, ZHP, had 
modified the process of synthesis previously using tribu-
tyltin azide which led to formation of N–nitrosamines. In 
this modification (Figure 4), tributyltin azide (Figure 3B) 
used for the nitril reaction was replaced with much che-
aper sodium azide (NaN3). This could have been conclu-
ded, among others, based on the fact that in 2014, ZHP 
published the patent number CN104045602A (translated 
title: “Improved method to synthesize the tetrazole moiety 
of valsartan”), in which it patented an improved synthesis 
method without the use of an organic tin compound [20, 
22]; this also indicates an economic background of this 
change. For simplification, the schematic representation 
of this reaction in Figure 4 shows hydrogen azide (HN3) 
which is created in an acidic environment from sodium azi-
de added to the reagent mixture. Following this reaction, 
similarly to the process described above, the resultant 
tetrazole derivative is hydrolyzed (Figure 4C) to create the 
actual API — valsartan.
Sodium azide used for this synthesis modification is 
a salt, and thus it poorly dissolves in organic solvents that 
are usually used for the synthesis of the tetrazole moie-
ty, such as dimethylformamide (DMF) [19]. Probably also 
for that reason, sodium azide was added to the reagent 
mixture in some excess, which in turn necessitated later 
removal of unreacted sodium azide by adding sodium nitri-
te (NaNO2), as could be concluded from one of the patents 
[20, 22] which also recommends adding sodium nitrite in 
an excess due to toxicity of sodium azide. Sodium nitrite 
inorganic azides (hydrogen azide [HN3] derivatives), leading 
to the formation of tetrazole derivatives.
One of the most commonly used methods to synthesi-
ze the tetrazole ring in sartan molecules (including that of 
valsartan) is a reaction that uses an organic azide, azido(n-
-tributyl)stannane or tri(n-butyl)tin azide, commonly known 
as tributyltin azide [17]. This reaction involves adding tri-
butyltin azide (Figure 3B) to a nitril compound (Figure 3A) 
that is an intermediate molecule in the valsartan synthe-
sis pathway, which yields a stannyl tetrazole compound 
(Figure 3C) [18].
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is a water-soluble salt, known for years as a reagent which 
may generate N–nitrosamines, particularly in the presence 
of secondary amines [23].
Further investigations seem to suggest that the other 
necessary factor that contributed to valsartan contami-
nation with N-nitrosamines was the use of DMF as a sol-
vent, releasing a secondary amine (mostly dimethylamine 
[DMA]), present either as an impurity and/or as a break-
down product due to specific reaction conditions.
Thus, two compounds that quite easily react with each 
other with formation of N–nitrosamines were simultane-
ously present in the reagent mixture. Sodium nitrite left 
after neutralization of azide may enter secondary/undesir-
able reactions, including N–nitrosylation of organic amines 
which leads to the formation of N–nitrosamines [24, 25]. 
In this way, NDMA is formed by a reaction of sodium nitrite 
with DMA [18], NDEA by a reaction of nitrites with triethyl- 
amine (TEA) which is used in some sartan synthesis pro-
cesses, and NDIPA found in valsartan manufactured by 
Signa S.A. de C.V. is formed by a reaction of nitrites with di-
isopropylamine (DIPA), also used in some sartan synthesis 
processes [8, 26]. Finally, NMBA detected in losartan po-
tassium manufactured by Hetero Labs is generated by the 
reaction between nitrities and a cyclic tertiary amine used 
as a solvent, N-methyl-2-pyrrolidone (NMP) [8].
In summary, a modification introduced by some API 
manufacturers, whereby sodium azide was substituted 
for tributyltin azide — along with an unfortunate choice 
of solvents/reagents — has likely been the major factor 
responsible for formation of toxic N–nitrosamines.
Toxicity of nitrosamines
N–nitrosamines show mutagenic, teratogenic/embryotoxic, 
and genotoxic properties. In addition, they exert a very 
potent carcinogenic effect, and may damage the liver [23]. 
Since Barnes and Magee had discovered carcinogenic 
properties of NDMA (leading to the development of hepatic 
tumours) in 1956, more than 300 nitrosamines were tested 
and about 90% of them (approximately 300 compounds) 
were found to be carcinogenic in many animal species 
[27, 28]. N–nitrosamines are commonly present in the 
Figure 3. Synthesis of the tetrazole ring at the 5-position during the conventional valsartan synthesis process. Nitrogen atoms forming 
the tetrazole ring are marked with colours: A. Nitril compound; B. Tributyltin azide; C. Stannyl tetrazole compound
A B C
Figure 4. A simplified scheme of a tetrazole derivative synthesis from a respective nitrile and hydrogen azide released from sodium azide 
during an alternative valsartan synthesis process. Nitrogen atoms forming the tetrazole ring are marked with colours: A. Nitril compound; 
B. Hydrogen azide. C. Resultant compound (valsartan methyl esther) with tetrazole moiety at the 5-position
A B C
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human environment, for example in cold cuts and smoked 
meats, tobacco smoke, purified drinking water, rubber, and 
some plastics [27, 29].
N–nitrosamines are pre-carcinogens metabolized in 
the body to actual carcinogens, in particular carbenium 
cations, which show potent alkylating properties towards 
purine and pyrimidine bases present in proteins and nucleic 
acids (DNA, RNA) [24, 27]. This explains the mutagenic and 
carcinogenic effects of most N-nitrosamines and their toxi-
city already at very low levels, even as low as 1 μg/L [24].
However, when comparing the lowest concentrations 
required for the carcinogenic effect of NDMA in animal 
experiments with average exposure in humans, it has 
been found that the average daily exposure (from foods 
and water) in Western countries is many times lower that 
the no observed effect level (NOEL) in animals, although 
the number of animals in the cited experiments has been 
admittedly limited [27].
It has been estimated that in Western Europe, the ave-
rage individual daily consumption of volatile nitrosamines 
is 0.2–0.3 μg [27]. In summer 2018, some valsartan sam-
ples were found to contain 3.4 to 120 ppm NDMA (average 
66.5 ppm) [27]. It has been calculated that with nitrosa-
mine contamination at the level of 120 ppm (= 120 μg/g), 
a daily sartan dose of 160 mg would contain as much as 
19 μg of NDMA in one tablet. Compared with the daily dose 
consumed with food, taking just one tablet containing con-
taminated valsartan would thus mean that N–nitrosamine 
consumption is increased many times compared to the 
usual intake [27]. Taking into account that N–nitrosamines 
are toxic already in the ppm range doses, it has been clear 
that many processes of sartan synthesis must undergo or 
is already undergoing strict verification.
Analytical aspects
Many methods are available to detect even very low levels 
of N–nitrosamines. In addition, many new actions have 
been taken after these compounds were detected in 
sartans. Official Medicines Control Laboratories (OMCL) 
collaborating within the General European OMCL Network 
(GEON) have rapidly developed various methods for 
detecting trace amounts of NDMA and NDEA in valsartan 
and other sartans. Participants in this project included the 
Irish Public Analyst’s Laboratory in Galway (PALG), French 
OMCL in the Montpellier Agence National de Sécurité de 
Medicament et de Produits de Sante (ANSM), and the 
German Chemischen und Veterinäruntersuchungsamt 
(CVUA) in Karlsruhe; a short summary of the introduced 
methods has been provided in the paper by Buschmann and 
Holzgrabe [26]. In the future, comprehensive monitoring of 
the drug synthesis process using analytical methods, taking 
into account all known and potential (including theoretical) 
impurities at the each step of API manufacturing, will be 
crucially important [26].
Summary and conclusions
An ill-considered modification of the valsartan synthesis 
process by some API manufacturers has led to the so-
called “valsartan scandal” related to the detection of 
trace amounts of carcinogenic N–nitrosamines both in the 
drug products and APIs. On one hand, this situation drew 
attention to the manufacturing processes of these drugs 
and withdrawal of contaminated products, but on the oth-
er hand, it also provoked fear of sartans in general, also 
those synthesized using methods not associated with the 
formation of toxic N–nitrosamines. Sartans remaining on 
the market are tightly monitored by drug safety agencies, 
and the resulting detailed toxicological analyses of potential 
(both identified and theoretically possible) impurities have 
allowed establishing updated requirements for the drug 
product composition. An example of such new regulations 
resulting from the valsartan scandal are new monographs 
of tetrazole ring-containing sartans published on July 1, 
2019 (effective Jan 1, 2020), included in the European 
Pharmacopoeia, 10th edition [30, 31] and specifying, among 
others, acceptable levels of N–nitrosamines in the transi-
tion period. After this period (i.e., since April 2021) sartans 
will not be allowed to contain detectable amounts of NDMA 
and NDEA, equivalent to less than 0.03 ppm (μg/g) [32]. 
It has also been noted that the manufacturing processes 
of other drugs which might also lead to the formation of 
N–nitrosamines need to be similarly investigated.
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Streszczenie
Pod koniec czerwca 2018 roku w niektórych lekach z grupy antagonistów receptora AT1 dla angiotensyny II (sar-
tanów) stosowanych w nadciśnieniu tętniczym wykryto niewielkie ilości silnie rakotwórczego zanieczyszczenia 
N-nitrozodimetyloaminą (NDMA) z grupy N-nitrozoamin. Do lipca 2019 zidentyfikowano łącznie cztery N-nitrozoaminy 
stanowiące zanieczyszczenia sartanów — NDMA, N–nitrozodietyloaminę, N–nitrozodiizopropyloaminę oraz kwas N-nitro-
zo-N-metylo-4-aminomasłowy, a także siedmiu wytwórców trzech skażonych substancji czynnych (walsartanu, losartanu, 
irbesartanu) pochodzących z Chin, Indii oraz Meksyku. Związki te przedostawały się do produktów leczniczych prawdopo-
dobnie wskutek nieprzemyślanych modyfikacji syntezy. Liczbę osób, którym przepisano sam skażony walsartan, w skali 
światowej szacuje się na około 20 milionów.
W pracy omówiono miejsce sartanów w leczeniu w kontekście fizjologicznego znaczenia układu renina–angiotensy-
na–aldosteron oraz rolę ugrupowania tetrazolowego w mechanizmie ich działania receptorowego. Scharakteryzowano 
syntezę ugrupowania tetrazolowego oraz jej modyfikacje jako możliwe przyczyny pojawienia się zanieczyszczeń nitro-
zoaminowych w sartanach. Pokrótce przedstawiono także toksykologiczne właściwości nitrozoamin. Fakt, że związki te 
przedostawały się do leków przez co najmniej 5 lat niewykryte i bez wiedzy organów odpowiedzialnych za bezpieczeń-
stwo leków, obnażył rażące niedostosowanie do rzeczywistości systemu mającego gwarantować bezpieczeństwo pro-
duktów leczniczych. Dlatego „afera walsartanowa” wymusiła zmiany niektórych regulacji dotyczących leków, zwłaszcza 
wymagania dotyczące procedur analitycznych.
Słowa kluczowe: sartany, zanieczyszczenia substancji czynnych leków, nitrozoaminy, chemizm pochodnych tetrazolu
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